Company intelligence / Profile preview

Code Biotherapeutics

Hatfield, Pennsylvania, United Statescodebiotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Code Biotherapeutics has not yet reported clinical results as its programs are in preclinical or discovery stages. The company’s lead research focuses on Duchenne Muscular Dystrophy and other genetic disorders using its proprietary non‑viral gene delivery technology[6].

Therapeutic areas: ImmunologyRare DiseasesNeurologyEndocrinology
Modalities: Gene therapy (non-viral)siRNA
Industry: Biotech

Drug pipeline

2 assets

3DNA-based gene therapy for Duchenne Muscular Dystrophy

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Collaboration with KSM Research and Innovation’s Biobank to accelerate drug development[4]. Additional strategic partnerships for select programs are mentioned but not detailed publicly[1].

Beyond the preview

Go deeper on Code Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Code Biotherapeutics.

Explore the full profile